AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33487103 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrofibrosis group
Number of subjects: 539
Study 34376241 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation
Number of subjects: 170
Study 34376241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 170
Study 34224690 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with S-EPAP
Number of subjects: 19
Study 34224690 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with T-EPAP
Number of subjects: 19
Study 34224690 — intervention group
Group type: COMPARATOR
Intervention: No NIV
Number of subjects: 19
Study 32324024 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-sampling phase with perceived actual contingency (Experiment 1)
Number of subjects: 0
Study 32324024 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-sampling phase with inferred pseudocontingency (Experiment 2a and b)
Number of subjects: 0
Study 32324024 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-sampling phase in reward-rich environments
Number of subjects: 0
Study 32324024 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-sampling phase in reward-impoverished environments
Number of subjects: 0
Study 35738650 — intervention group
Group type: EXPERIMENTAL
Intervention: rfMDA
Number of subjects: 8948
Study 35738650 — intervention group
Group type: COMPARATOR
Intervention: RAVC
Number of subjects: 8948
Study 35738650 — intervention group
Group type: EXPERIMENTAL
Intervention: rfMDA+RAVC
Number of subjects: 8948
Study 35738650 — intervention group
Group type: COMPARATOR
Intervention: RACD
Number of subjects: 8948
Study 32524612 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled glass (340-ml glasses of beer or wine)
Number of subjects: 162
Study 32524612 — intervention group
Group type: COMPARATOR
Intervention: Plain glass (control, 340-ml glasses of beer or wine)
Number of subjects: 162
Study 34921902 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I and T levels extracted from electronic health records (EHR)
Number of subjects: 0
Study 35057782 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional + VR-assisted teaching (additional VR session took approximately 25-45 minutes)
Number of subjects: 44
Study 35057782 — intervention group
Group type: COMPARATOR
Intervention: Conventional classes (about 15 minutes)
Number of subjects: 44
Study 33625666 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy for 3 months in addition to pharmacological treatment
Number of subjects: 140
Study 33625666 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment only (Control)
Number of subjects: 140
Study 33625666 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 140
Study 32281269 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy‐led pathway
Number of subjects: 150
Study 32281269 — intervention group
Group type: COMPARATOR
Intervention: Physician‐led pathway
Number of subjects: 150
Study 32281269 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization
Number of subjects: 150
Study 32281269 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety and harm assessment
Number of subjects: 150
Study 35179176 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Skin
Number of subjects: 66
Study 35179176 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyle
Number of subjects: 66
Study 34053824 — intervention group
Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of people living with HIV)
Number of subjects: 1632
Study 34053824 — intervention group
Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of people living with hepatitis B)
Number of subjects: 1632
Study 34053824 — intervention group
Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of people living with hepatitis C)
Number of subjects: 1632
Study 34053824 — intervention group
Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of people who inject drugs)
Number of subjects: 1632
Study 34053824 — intervention group
Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of sex workers)
Number of subjects: 1632
Study 34053824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1632
Study 36266559 — intervention group
Group type: EXPERIMENTAL
Intervention: StayFitLonger (SFL) computerized multidomain training program
Number of subjects: 120
Study 36266559 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention (basic mobilization exercises and access to video games)
Number of subjects: 120
Study 33927278 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective CPAP (n=12)
Number of subjects: 24
Study 33927278 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP (n=12)
Number of subjects: 24
Study 35830233 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted telephone intervention
Number of subjects: 49
Study 35830233 — intervention group
Group type: COMPARATOR
Intervention: Traditional telephone intervention
Number of subjects: 49
Study 35830233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 33483828 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pre-visit laboratory testing before the first visit
Number of subjects: 594
Study 33483828 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-visit testing)
Number of subjects: 594
Study 32723997 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic isophane insulin injection
Number of subjects: 119
Study 35316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-mini-percutaneous nephrolithotomy in modified flank free supine position (Group A)
Number of subjects: 122
Study 35316078 — intervention group
Group type: COMPARATOR
Intervention: Ultra-mini-percutaneous nephrolithotomy in prone position (Group B)
Number of subjects: 122
Study 33123888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking using coal
Number of subjects: 35
Study 33123888 — intervention group
Group type: COMPARATOR
Intervention: Cooking using liquefied petroleum gas (LPG) or electricity
Number of subjects: 35
Study 33123888 — intervention group
Group type: COMPARATOR
Intervention: Kitchens with range hoods
Number of subjects: 35
Study 33123888 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitchens without range hoods
Number of subjects: 35
Study 32064832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth breathing subjects
Number of subjects: 50
Study 32064832 — intervention group
Group type: COMPARATOR
Intervention: Nasal breathing subjects
Number of subjects: 50
Study 32064832 — intervention group
Group type: EXPERIMENTAL
Intervention: Older mouth breathing subjects
Number of subjects: 50
Study 35283116 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ACTH (1 mg)
Number of subjects: 38
Study 35283116 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone (6 mg)
Number of subjects: 38
Study 34546914 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application intervention
Number of subjects: 644
Study 34546914 — intervention group
Group type: COMPARATOR
Intervention: Measurement-only control arm
Number of subjects: 644
Study 36454970 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation - low frequency
Number of subjects: 105
Study 36454970 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation - high frequency
Number of subjects: 105
Study 36454970 — intervention group
Group type: EXPERIMENTAL
Intervention: Aussie median frequency
Number of subjects: 105
Study 36454970 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential median frequency
Number of subjects: 105
Study 36454970 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage stimulation
Number of subjects: 105
Study 33438344 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 54
Study 33438344 — intervention group
Group type: COMPARATOR
Intervention: ultrathin Descemet stripping automated endothelial keratoplasty (DSAEK)
Number of subjects: 54
Study 33438344 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 54
Study 33438344 — intervention group
Group type: COMPARATOR
Intervention: DMEK and DSAEK
Number of subjects: 54
Study 36262871 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Temperature Plasma Radiofrequency Ablation (LTPRA)
Number of subjects: 106
Study 36262871 — intervention group
Group type: COMPARATOR
Intervention: Dynamic-system surgery under nasal endoscope
Number of subjects: 106
Study 36262871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LTPRA and dissection)
Number of subjects: 106
Study 33999503 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokeless moxibustion (SLM)
Number of subjects: 60
Study 33999503 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 33999503 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke moxibustion (SM)
Number of subjects: 60
Study 33513653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 33513653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 32150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine HFA MDI at doses above 125 μg
Number of subjects: 0
Study 32150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine HFA MDI at doses 125-250 μg
Number of subjects: 0
Study 32150492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study 32150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine CFC MDI (220 μg/inhalation)
Number of subjects: 0
Study 36259487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided platelet-rich plasma (PRP) injection combined with drugs
Number of subjects: 80
Study 36259487 — intervention group
Group type: COMPARATOR
Intervention: Drugs alone (Control group)
Number of subjects: 80
Study 36259487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PRP injection combined with drugs
Number of subjects: 80
Study 33884840 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 33884840 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 0
Study 33441384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 1357
Study 33441384 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Number of subjects: 1357
Study 33441384 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1357
Study 33568603 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information (Group I)
Number of subjects: 270
Study 33568603 — intervention group
Group type: COMPARATOR
Intervention: Video of surgery on manikins (Group II)
Number of subjects: 270
Study 33568603 — intervention group
Group type: COMPARATOR
Intervention: Video of surgery on a real patient (Group III)
Number of subjects: 270
Study 36100118 — intervention group
Group type: EXPERIMENTAL
Intervention: AGV-Ologen
Number of subjects: 33
Study 36100118 — intervention group
Group type: COMPARATOR
Intervention: AGV
Number of subjects: 33
Study 32149709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold (BRS)
Number of subjects: 60
Study 35261115 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (left and right VLPFC)
Number of subjects: 120
Study 35261115 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (right VLPFC)
Number of subjects: 120
Study 35261115 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS (vertex)
Number of subjects: 120
Study 32240866 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-electrode mapping (MEM)
Number of subjects: 114
Study 32240866 — intervention group
Group type: COMPARATOR
Intervention: Conventional activation mapping (CAM)
Number of subjects: 114
Study 36057163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric-adult transition program
Number of subjects: 12
Study 36057163 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals' involvement
Number of subjects: 12
Study 33845626 — intervention group
Group type: EXPERIMENTAL
Intervention: CO-OP + OPC (Cognitive Orientation to daily Occupational Performance Approach with Occupational Performance Coaching)
Number of subjects: 0
Study 33845626 — intervention group
Group type: COMPARATOR
Intervention: CO-OP (Cognitive Orientation to daily Occupational Performance Approach)
Number of subjects: 0
Study 32081787 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell receptor (TCR) repertoire analysis in patients with steroid nonresponsive aGVHD
Number of subjects: 0
Study 32081787 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Vβ20 and Vβ29
Number of subjects: 0
Study 32081787 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR repertoire analysis in patients with shared HLA mismatch
Number of subjects: 0
Study 35678177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 118
Study 35678177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 35678177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (night administration)
Number of subjects: 118
Study 32100190 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous estradiol
Number of subjects: 155
Study 35428609 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg/kg on day 1, followed by 80 mg/kg on days 2 and 3, plus granisetron 3 mg/m2 on day 1 and dexamethasone on days 1 to 3
Number of subjects: 120
Study 35428609 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant 125 mg/kg on day 1 and placebo on days 2 and 3, plus granisetron 3 mg/m2 on day 1 and dexamethasone on days 1 to 3
Number of subjects: 120
Study 32537707 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component training (including dual-task, dynamic balance, endurance and strength exercises) for 16 weeks (twice per week for 45–60 min)
Number of subjects: 24
Study 32537707 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 24
Study 35732849 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (R)
Number of subjects: 68
Study 35732849 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 68
Study 34627582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil and ambrisentan combination therapy
Number of subjects: 27
Study 34627582 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil monotherapy
Number of subjects: 27
Study 35567889 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Vivomix 112 billion, one capsule a day for 16 weeks)
Number of subjects: 100
Study 35567889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35468153 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG seropositivity testing
Number of subjects: 459
Study 35468153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination status
Number of subjects: 459
Study 35468153 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 459
Study 35468153 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare role
Number of subjects: 459
Study 35468153 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace setting
Number of subjects: 459
Study 35468153 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU vs. ambulatory clinic
Number of subjects: 459
Study 32911306 — intervention group
Group type: EXPERIMENTAL
Intervention: teriflunomide 14 mg
Number of subjects: 751
Study 32911306 — intervention group
Group type: EXPERIMENTAL
Intervention: teriflunomide 7 mg/14 mg
Number of subjects: 751
Study 32911306 — intervention group
Group type: EXPERIMENTAL
Intervention: teriflunomide 14 mg/14 mg
Number of subjects: 751
Study 32911306 — intervention group
Group type: COMPARATOR
Intervention: placebo/teriflunomide 14 mg
Number of subjects: 751
Study 36454520 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related readmission within 12 months post-discharge
Number of subjects: 2637
Study 36454520 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially preventable drug-related revisits
Number of subjects: 2637
Study 33305744 — intervention group
Group type: EXPERIMENTAL
Intervention: Group RD: 30 ml of 0.5% Ropivacaine + 0.75 mcg/kg Dexmedetomidine
Number of subjects: 60
Study 33305744 — intervention group
Group type: COMPARATOR
Intervention: Group RS: 30 ml of 0.5% Ropivacaine + 1 ml Normal Saline
Number of subjects: 60
Study 35791646 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPR108 + metformin
Number of subjects: 150
Study 35791646 — intervention group
Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 150
Study 33563040 — intervention group
Group type: EXPERIMENTAL
Intervention: fruquintinib
Number of subjects: 416
Study 32787896 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week home-based telerehabilitation virtual reality (VR) program
Number of subjects: 24
Study 32787896 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy focusing on task-related upper-limb treatments
Number of subjects: 24
Study 35792882 — intervention group
Group type: EXPERIMENTAL
Intervention: VGT-309
Number of subjects: 2
Study 34269894 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic/systematic CR referral
Number of subjects: 0
Study 34269894 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician CR encouragement at the bedside
Number of subjects: 0
Study 34269894 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised program models
Number of subjects: 0
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: < 3.0 MET-h/wk
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 18.0 MET-h/wk
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0 h/wk (light to moderate intensity)
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 1.5 h/wk (light to moderate intensity)
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0 h/wk (vigorous intensity)
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 1.0 h/wk (vigorous intensity)
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: < 1.0 h/wk (brisk walking)
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 3.0 h/wk (brisk walking)
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0 h/wk (muscle strengthening)
Number of subjects: 1696
Study 35944235 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 0.5 h/wk (muscle strengthening)
Number of subjects: 1696
Study 32929783 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst spinal cord stimulation (SCS)
Number of subjects: 69
Study 32929783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic spinal cord stimulation (SCS)
Number of subjects: 69
Study 32929783 — intervention group
Group type: COMPARATOR
Intervention: Both modes (burst and tonic)
Number of subjects: 69
Study 32631447 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) preparation, titrated doses ranging from 2.5 mg/2.5 mg to 30 mg/30 mg per day, administered as an oral solution for a total of 4 weeks (2 weeks titration + 2 weeks stable dose).
Number of subjects: 150
Study 32631447 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) preparation.
Number of subjects: 150
Study 32631447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral solution).
Number of subjects: 150
Study 32572862 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior POEM
Number of subjects: 111
Study 32572862 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior POEM
Number of subjects: 111
Study 32572862 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 111
Study 35667000 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 47
Study 35667000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 47
Study 35667000 — intervention group
Group type: COMPARATOR
Intervention: Well-Rested (WR)
Number of subjects: 47
Study 32106733 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 75% group (greater initial migration)
Number of subjects: 39
Study 32106733 — intervention group
Group type: COMPARATOR
Intervention: < 75% group (less initial migration)
Number of subjects: 39
Study 36164152 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus Carfilzomib and Dexamethasone (Isa-Kd)
Number of subjects: 302
Study 36164152 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib and Dexamethasone (Kd)
Number of subjects: 302
Study 32538212 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 217
Study 32538212 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 217
Study 32538212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake
Number of subjects: 217
Study 35689421 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF® Blu Voile Sunscreen
Number of subjects: 39
Study 33676886 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized digital and human direct oral anticoagulant adherence intervention (medication management smartphone app, daily app-based reminders, adaptive text messaging, and phone-based counseling for severe nonadherence)
Number of subjects: 139
Study 33676886 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 139
Study 33676886 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized digital and human direct oral anticoagulant adherence intervention
Number of subjects: 139
Study 35527666 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral LTRA 10 mg
Number of subjects: 50
Study 35527666 — intervention group
Group type: COMPARATOR
Intervention: Step-up medium dose of ICS
Number of subjects: 50
Study 35527666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50